Literature DB >> 7517173

Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction.

R J Mairs1, A Livingstone, M N Gaze, T E Wheldon, A Barrett.   

Abstract

Radiolabelled meta-iodobenzylguanidine (mIBG) currently provides one of the most promising options for targeted radiotherapy of neuroblastoma. No means currently exists for prediction of mIBG uptake in tumour cells of individual patients other than semiquantitative inferences from diagnostic scanning which depend on the continued existence of a macroscopic tumour mass. A biological rapid assay which could be applied at initial biopsy would be invaluable in selecting patients for therapeutic strategies which incorporate radiolabelled mIBG. We have assessed the expression of the noradrenaline transporter gene in six human neuroblastoma cell lines and in three non-neural crest-derived cell lines using reverse transcription followed by the polymerase chain reaction. Transcription of this gene was observed in five out of six neuroblastoma cell lines but in none of the control cells. A highly significant correlation was established (P < 0.01) between gene expression and active cellular accumulation of mIBG. It is suggested that semiquantitative evaluation of noradrenaline transporter gene transcripts may be predictive of mIBG uptake by tumours in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517173      PMCID: PMC2033329          DOI: 10.1038/bjc.1994.256

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones.

Authors:  J L Biedler; S Roffler-Tarlov; M Schachner; L S Freedman
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

2.  A human cell line from a pleural effusion derived from a breast carcinoma.

Authors:  H D Soule; J Vazguez; A Long; S Albert; M Brennan
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

3.  Variation among human 28S ribosomal RNA genes.

Authors:  I L Gonzalez; J L Gorski; T J Campen; D J Dorney; J M Erickson; J E Sylvester; R D Schmickel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

4.  Definition of a continuous human cell line derived from neuroblastoma.

Authors:  J J Tumilowicz; W W Nichols; J J Cholon; A E Greene
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

5.  Establishment and characterization of human neuroblastoma cell lines.

Authors:  H R Schlesinger; J M Gerson; P S Moorhead; H Maguire; K Hummeler
Journal:  Cancer Res       Date:  1976-09       Impact factor: 12.701

6.  Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.

Authors:  B Shapiro; J E Copp; J C Sisson; P L Eyre; J Wallis; W H Beierwaltes
Journal:  J Nucl Med       Date:  1985-06       Impact factor: 10.057

7.  Specific uptake of m-[125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH.

Authors:  J Buck; G Bruchelt; R Girgert; J Treuner; D Niethammer
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701

8.  Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.

Authors:  T C Hamilton; R C Young; W M McKoy; K R Grotzinger; J A Green; E W Chu; J Whang-Peng; A M Rogan; W R Green; R F Ozols
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

9.  Biological properties of a tumour cell line (NB1-G) derived from human neuroblastoma.

Authors:  R Carachi; T Raza; D Robertson; T W Wheldon; L Wilson; A Livingstone; V van Heyningen; G Spowart; P Middleton; J R Gosden
Journal:  Br J Cancer       Date:  1987-04       Impact factor: 7.640

10.  Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix.

Authors:  W F SCHERER; J T SYVERTON; G O GEY
Journal:  J Exp Med       Date:  1953-05       Impact factor: 14.307

View more
  13 in total

1.  Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue.

Authors:  Jennifer E Gains; Neil J Sebire; Veronica Moroz; Keith Wheatley; Mark N Gaze
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-17       Impact factor: 9.236

2.  High ¹²³I-MIBG uptake in neuroblastic tumours indicates unfavourable histopathology.

Authors:  Wolfgang Peter Fendler; Henriette Ingrid Melzer; Christoph Walz; Dietrich von Schweinitz; Eva Coppenrath; Irene Schmid; Peter Bartenstein; Thomas Pfluger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-16       Impact factor: 9.236

3.  MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

Authors:  Steven G DuBois; Rajen Mody; Arlene Naranjo; Collin Van Ryn; Douglas Russ; Derek Oldridge; Susan Kreissman; David L Baker; Marguerite Parisi; Barry L Shulkin; Harrison Bai; Sharon J Diskin; Vandana Batra; John M Maris; Julie R Park; Katherine K Matthay; Gregory Yanik
Journal:  Pediatr Blood Cancer       Date:  2017-04-06       Impact factor: 3.167

Review 4.  Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.

Authors:  K K Matthay; B Shulkin; R Ladenstein; J Michon; F Giammarile; V Lewington; A D J Pearson; S L Cohn
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

Review 5.  Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.

Authors:  Steven G DuBois; Katherine K Matthay
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

6.  Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.

Authors:  William Temple; Lori Mendelsohn; Grace E Kim; Erin Nekritz; W Clay Gustafson; Lawrence Lin; Kathy Giacomini; Arlene Naranjo; Collin Van Ryn; Gregory A Yanik; Susan G Kreissman; Michael Hogarty; Katherine K Matthay; Steven G DuBois
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-04       Impact factor: 9.236

7.  Targeted radiotherapy: microgray doses and the bystander effect.

Authors:  Robert J Mairs; Natasha E Fullerton; Michael R Zalutsky; Marie Boyd
Journal:  Dose Response       Date:  2007-04-20       Impact factor: 2.658

8.  Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group.

Authors:  Steven G Dubois; Ethan Geier; Vandana Batra; Sook Wah Yee; John Neuhaus; Mark Segal; Daniel Martinez; Bruce Pawel; Greg Yanik; Arlene Naranjo; Wendy B London; Susan Kreissman; David Baker; Edward Attiyeh; Michael D Hogarty; John M Maris; Kathleen Giacomini; Katherine K Matthay
Journal:  Int J Mol Imaging       Date:  2012-09-25

9.  The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro.

Authors:  A Armour; S H Cunningham; M N Gaze; T E Wheldon; R J Mairs
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.

Authors:  S H Cunningham; R J Mairs; T E Wheldon; P C Welsh; G Vaidyanathan; M R Zalutsky
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.